RespireRx (Formerly Known As Cortex Pharmaceuticals, Inc.)

163 articles with RespireRx (Formerly Known As Cortex Pharmaceuticals, Inc.)

• Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI

  2/9/2021

  RespireRx Pharmaceuticals Inc., has been up listed from the OTC Pink Market and returns to the OTCQB Venture Market, effective with opening of the markets , Monday, February 8, 2021.

• RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences

  1/8/2021

  RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPID) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Company’s senior management will participate in two virtual investor conferences in January

• RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split

  1/5/2021

  RespireRx Pharmaceuticals Inc., has, on January 4, 2021, filed with the Secretary of State of the State of Delaware a Sixth Certificate of Amendment to its Second Restated Certificate of Incorporation.

• RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury

  10/6/2020

  RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication by Dr. David Fuller and his colleagues of a review article entitled “Ampakines Stimulate Phrenic Motor Output after Cervical Spinal Cord Injury” in a special issue of the peer-reviewed journal,

• RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development

  9/25/2020

  RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment on September 15, 2020, of David Dickason as Senior Vice President Pre-clinical Product Development.

• RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property

  8/4/2020

  RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), has historically been and remains a leader in the research and development of ampakines for a variety of central nervous system (CNS) disorders and cannabinoids for the treatment of sleep-related breathing disorders. On March 2, 2020, the Company and the UWM Research Foundation, Inc. (“UWMRF”), an affiliate of the University of Wisconsin-Milwaukee entered into an opti

• RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer

  8/3/2020

  RespireRx Pharmaceuticals Inc., is pleased to announce that , Mr. Tim Jones and RespireRx have transitioned from the provisional period that commenced on May 6, 2020 to the three year, long-term portion of the employment contract with Mr. Jones as its President and Chief Executive Officer.

• RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer

  5/6/2020

  Dr. Arnold S. Lippa, Ph.D. to Continue as Executive Chairman of the Board of Directors and Chief Scientific Officer

• RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.

  3/4/2020

  RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety of central nervous system disorders (CNS disorders) and cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that on March 2, 2020, the Company and the UWM Research Foundation, Inc. (“UWMRF”), an affiliate of the University of Wisconsin-

• RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report

  2/12/2020

  Glen Rock, N.J., Feb. 12, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”) indications, with a focus on obstructive sleep apnea, attention deficit hyperactivity disorder (“ADHD”), spinal cord injury and other neurological conditions, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties.  D

• RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications

  2/5/2020

  Glen Rock, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce the recent filing of a continuation-in-part patent application for its pending patent claiming novel doses, controlled release compositions and methods of use for cannabinoids, as well as a new U.S. Provisional Patent Application furt

• RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors

  2/3/2020

  Pleased to announce the unanimous appointment on January 28, 2020, of Tim Jones as a member of its board of directors to fill a vacancy.

• RespireRx Pharmaceuticals Inc. Announces Resignation of Dr. James S. Manuso

  6/19/2018

  RespireRx Pharmaceuticals Inc. announces the decision of Dr. James S. Manuso to resign as president, CEO, Vice Chairman and member of the Board of Directors (“Board”) of the Company, effective as of September 30, 2018

• RespireRx Pharma Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development

  12/18/2017

  RespireRx, is pleased to announce that a paper detailing the neurobiologic safety of the ampakine CX717 has been accepted for publication by Toxicological Sciences, the Journal of the American Society of Toxicology.

• RespireRx Pharmaceuticals Officers and Directors Elect to Forgive $2,356,733 of Past Due Cash Compensation and Receive Non-Qualified Stock Options to Reduce Balance Sheet Debt

  12/15/2017

  The Amendment increases the shares issuable under the plan by 3,946,799, from 3,038,461 shares to 6,985,260.

• RespireRx Pharmaceuticals Announces Publication of Phase IIB PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea

  11/30/2017

  The PACE paper is published in the journal SLEEP, the official publication of the Sleep Research Society, and the leading peer-reviewed journal in sleep and circadian science.

• RespireRx To Present At 2017 Rodman & Renshaw Conference

  9/11/2017

• RespireRx Files June 30, 2017 Quarterly Report On Form 10-Q And Provides Update

  8/28/2017

• RespireRx Announces Participation SLEEP 2017 In Boston, MA

  6/7/2017

• RespireRx Announces Positive Results From Phase 2B PACE Study Conducted By The University of Illinois Dronabinol Reduces Symptoms Of Obstructive Sleep Apnea

  12/27/2016